Tag

Your search for Access to therapy returned 18 results.


Real-world evaluation of eligibility for HCV therapy

In clinical practices in Italy, between January 2009 and February 2010, only 61% of patients with chronic hepatitis C were considered eligible for peginterferon/ribavirin. Reasons treatment was not indicated included patient’s age or mild disease stage. Italian Hepatologists may consider an IFN-based antiviral treatment not cost-effective in older patients ...

Read More


HCV therapy access reduces HCV-related deaths

A global reduction of HCV liver-related mortality is dependent on access to therapy Between 64 and 103 million individuals worldwide are estimated to be chronically infected with hepatitis C (HCV). Fortunately, with the advent of interferon-free therapy with SVR rates in pivotal phase 2 and 3 trials of between 92% and 100%, it’s possible to cure chronic HCV ...

Read More


Real-life HCV management in US urban center

Study provides a “real-life” snapshot of how HCV infection is being addressed in a major US urban center Acute hepatitis C infection is asymptomatic in 60-70% of individuals. Many people only learn that they are HCV-positive decades later, after their disease has progressed to cirrhosis, hepatocellular carcinoma, or liver failure. Unfortunately, 50-75% of ...

Read More


HCV linkage-to-care for baby boomers in the ED

Recent study highlights the necessity of providing HCV screening and linkage-to-care to baby boomer patients in the emergency department HCV-infected individuals are more likely to use the emergency department (ED) for care than any other healthcare venue. HCV antibody prevalence appears to be between 4-18% in the general ED population. Frequent users of the care ...

Read More


Viral load quantification: Hepatitis therapy barrier

Hepatitis viral load quantification is lacking in low- and middle-income countries, and this is a major barrier to the provision of therapies to patients who need them Viral load quantification is considered a mandatory component of the diagnostic work-up in all international liver society guidelines. Low- and middle-income countries typically lack access to viral ...

Read More


Hepatitis C: topical and comprehensive seminar

The Lancet has published a topical and comprehensive seminar on hepatitis C The March 2015 issue of the Lancet contains an authoritative seminar on hepatitis C (Webster DP, et al. Lancet. 2015;385:1124-1135). The Lancet is one of the world's leading medical journals; an independent and authoritative voice in global medicine. Dr. Daniel Webster and colleagues' ...

Read More


Can hepatitis C be eradicated in the US?

An important commentary by Brian Edlin and Emily Winkelstein, published in August 2014 in the journal Antiviral Research, outlined key steps that should be taken to accomplish the elimination of hepatitis C in the United States (Edlin BR, Winkelstein ER. Antiviral Res. 2014;110:79-93). This article is freely available on the online AJM Hepatitis C Resource Center ...

Read More


HCV RNA Testing in HCV Seropositive Patients

Only 48% of HCV Seropositive Patients Undergo HCV RNA Testing and Only 5% Initiate Therapy The Centers for Disease Control and Prevention recommends one-time hepatitis C virus (HCV) testing of individuals born between 1945 and 1965, with follow-up RNA testing for those with reactive serology. A study published last year in the journal Open Forum Infectious ...

Read More